Edwards Lifesciences Corp (EW)vsNovo Nordisk A/S (NVO)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 4994% more annual revenue ($309.06B vs $6.07B). NVO leads profitability with a 33.1% profit margin vs 17.7%. EW appears more attractively valued with a PEG of 2.14. NVO earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
NVO
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
EW profiles as a mature stock while NVO is a declining play — different risk/reward profiles.
EW carries more volatility with a beta of 0.93 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 55/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?